Algernon Pharmaceuticals Provides Final Summary on Accelerated Warrants
Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company is pleased to provide a final summary of the common share purchase warrants of the Company that were issued on November 1, 2019. The Company elected to exercise its acceleration right under the warrant indenture governing the November Warrants. Pursuant to the terms of the Indenture, the Company accelerated the expiry date of the …
Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to provide a final summary of the common share purchase warrants of the Company (the “November Warrants”), that were issued on November 1, 2019.
Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company, is pleased to announce that the external Data and Safety Monitoring Board has completed its latest review of the Phase 2b part of the Company’s Phase 2b3 human study of NP-120 for the treatment of COVID-19, and has provided approval for the Company to continue on with the Phase 3 part of the study. The DSMB is a committee of .
Algernon Highlights New Independent Research Review Identifying Ifenprodil as a Potential COVID-19 Treatment
Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company, is pleased to highlight an independent research review published in the January 5 th edition of the European Archives of Psychiatry and Clinical Neuroscience that identified Ifenprodil as a possible re-purposed drug candidate for the treatment of COVID-19. The Review focuses on the sigma-1 receptor in the endoplasmic reticulum, a …
Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company, is pleased to highlight an independent research review (the “Review”) published in the January 5 th edition of the European Archives of Psychiatry and Clinical Neuroscience that identified Ifenprodil as a possible re-purposed drug candidate for the treatment of COVID-19.